A global powerhouse and forerunner on the international stage, the U.S. biopharmaceutical industry is recognized as the most prominent proponent of medical innovation around the world. As the industry moves from treatments towards cures and pipelines are developed around the notion of precision medicine, more and more life-changing therapies are entering the market. With an increasing amount of innovation stemming from small biotechnology companies and university spin-offs, the importance of fostering innovation and providing a supportive framework is paramount. Regional hubs with flourishing innovation ecosystems are notable for the incentives they offer and, as such, have become centers for innovation and knowledge exchange. GBR’s 2018 U.S. Biopharmaceuticals Pre-release shines a spotlight on the Boston/Cambridge area and San Francisco Bay Area as top destinations for investment and biopharmaceutical activity.